Analysts Expect Horizon Pharma PLC (HZNP) to Post $0.22 EPS
Wall Street brokerages forecast that Horizon Pharma PLC (NASDAQ:HZNP) will announce earnings per share (EPS) of $0.22 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Horizon Pharma PLC’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.28. Horizon Pharma PLC posted earnings of $0.70 per share during the same quarter last year, which would indicate a negative year over year growth rate of 68.6%. The business is expected to report its next earnings results on Monday, November 6th.
According to Zacks, analysts expect that Horizon Pharma PLC will report full-year earnings of $1.04 per share for the current financial year, with EPS estimates ranging from $0.87 to $1.16. For the next financial year, analysts anticipate that the firm will report earnings of $1.16 per share, with EPS estimates ranging from $0.95 to $1.33. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Horizon Pharma PLC.
Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The business had revenue of $289.51 million for the quarter, compared to analysts’ expectations of $237.01 million. During the same quarter in the prior year, the firm posted $0.56 EPS. The company’s revenue was up 12.5% compared to the same quarter last year.
A number of analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $17.00 target price (up previously from $13.00) on shares of Horizon Pharma PLC in a research note on Wednesday, August 9th. UBS AG set a $16.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Wednesday, June 7th. Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BMO Capital Markets reiterated a “buy” rating and issued a $17.00 target price on shares of Horizon Pharma PLC in a research note on Friday, July 28th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of Horizon Pharma PLC in a research note on Thursday, September 28th. They issued a “buy” rating and a $16.00 target price for the company. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $18.00.
Horizon Pharma PLC (NASDAQ HZNP) opened at 13.67 on Thursday. The stock’s market cap is $2.23 billion. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $21.98. The firm’s 50 day moving average price is $12.93 and its 200-day moving average price is $12.75.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/05/analysts-expect-horizon-pharma-plc-hznp-to-post-0-22-eps.html.
Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can lifted its holdings in shares of Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 1,378 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its holdings in shares of Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 500 shares in the last quarter. Family Management Corp purchased a new stake in shares of Horizon Pharma PLC in the second quarter worth about $131,000. Ballentine Partners LLC purchased a new stake in shares of Horizon Pharma PLC in the second quarter worth about $139,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Horizon Pharma PLC in the first quarter worth about $151,000. 82.33% of the stock is currently owned by hedge funds and other institutional investors.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.